Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17832
Shown on this page
12
Current sort
Recently updated
Location scope
Chicago, IL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Chicago, Illinois. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 721–732 of 17,832 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Not applicable Interventional

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT06911632
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions
ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator
Device · Procedure
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting Phase 1 Interventional

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

NCT04644770
View directory record Official record
Conditions
Prostatic Neoplasms, Adenocarcinoma
Interventions
JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting No phase listed Observational

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Murrieta, California • Rialto, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Completed No phase listed Observational Results available

Philips Intracardiac Echocardiography (ICE) Clinical Registry

NCT04950192
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions
ICE Image guidance
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Recruiting Phase 3 Interventional

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

NCT07321652
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Zanubrutinib, Sonrotoclax, Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection, Survey Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
261
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 213 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting Phase 2 Interventional

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616
View directory record Official record
Conditions
Alzheimer Disease
Interventions
JNJ-64042056, Placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
55 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting Phase 2 Interventional Results available

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

NCT04200443
View directory record Official record
Conditions
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Unresectable Soft Tissue Sarcoma
Interventions
Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Not yet recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

NCT07900633
View directory record Official record
Conditions
Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Apache Junction, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting Phase 2 Interventional

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

NCT06730100
View directory record Official record
Conditions
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Erdafitinib, Vinflunine, Docetaxel, Pembrolizumab, Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Drug · Device
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
26
States / cities
Anchorage, Alaska • Sacramento, California • St. Helena, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Terminated Not applicable Interventional Results available

Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)

NCT04696354
View directory record Official record
Conditions
Venous Ulcer of Leg
Interventions
IVUS, Continued Compression Therapy/Stockings
Diagnostic Test · Other
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Darien, Connecticut • Winter Park, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST
Active, not recruiting Phase 3 Interventional

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-200, Mitomycin C, Gemcitabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 1:50 PM EST